← Leaderboards
Zhenheng Guo
University Of Kentucky
$9,758,888
Attributed
$17,423,815
Total exposure
11
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,423,815 · 9
VA$0 · 2
By mechanism
R01$17,415,499 · 8
P41$8,316 · 1
I01$0 · 2
Top collaborators
- Ming C Gong26 shared
- Eugene Sangkeu Lee5 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- Ming C Gong$10,288,417
- Michael Paul Murphy$8,590,720
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingKnockout MiceAffectLinkAnimal ModelSmooth Muscle MyocytesHypertensionSchemePlayDiabetes MellitusCardiovascular SystemAgonistMolecularMouse ModelNew Therapeutic TargetNovel TherapeuticsAortaWomanPreventDiabeticBlood PressureGenesBlood VesselsDb/Db Mouse
Grant awards (42)
Targeting Endothelial Cell Mineralocorticoid Receptor Against Aortic Aneurysm in Females$721,911
R01 · FY2025 · HL · contact PI
Targeting GLP-1 receptor as a new chronotherapy against nondipping blood pressure in diabetes$695,237
R01 · FY2025 · HL
Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis$664,969
R01 · FY2025 · HL · contact PI
Targeting Endothelial Cell Mineralocorticoid Receptor Against Aortic Aneurysm in Females$721,911
R01 · FY2024 · HL · contact PI
Targeting GLP-1 receptor as a new chronotherapy against nondipping blood pressure in diabetes$681,332
R01 · FY2024 · HL
Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis$651,670
R01 · FY2024 · HL · contact PI
Targeting GLP-1 receptor as a new chronotherapy against nondipping blood pressure in diabetes$695,237
R01 · FY2023 · HL
Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis$664,969
R01 · FY2023 · HL · contact PI
Role of RhoA in small AAA growth$0
I01 · FY2023 · VA
Targeting GLP-1 receptor as a new chronotherapy against nondipping blood pressure in diabetes$695,237
R01 · FY2022 · HL
Targeting timing of food intake as a novel strategy against disruption of blood pressure circadian rhythm in diabetes$601,123
R01 · FY2022 · HL
Role of RhoA in small AAA growth$0
I01 · FY2022 · VA
A novel mechanism by which smooth muscle BMAL1 regulates IL-6 and sexual dimorphism of abdominal aortic aneurysm$641,381
R01 · FY2021 · HL
Targeting timing of food intake as a novel strategy against disruption of blood pressure circadian rhythm in diabetes$601,123
R01 · FY2021 · HL
Role of RhoA in small AAA growth$0
I01 · FY2021 · VA
A novel mechanism by which smooth muscle BMAL1 regulates IL-6 and sexual dimorphism of abdominal aortic aneurysm$626,752
R01 · FY2020 · HL
Targeting timing of food intake as a novel strategy against disruption of blood pressure circadian rhythm in diabetes$601,123
R01 · FY2020 · HL
Role of RhoA in small AAA growth$0
I01 · FY2020 · VA
Targeting timing of food intake as a novel strategy against disruption of blood pressure circadian rhythm in diabetes$704,321
R01 · FY2019 · HL
A novel mechanism by which smooth muscle BMAL1 regulates IL-6 and sexual dimorphism of abdominal aortic aneurysm$626,335
R01 · FY2019 · HL
Role of RhoA in small AAA growth$0
I01 · FY2019 · VA
A novel mechanism by which smooth muscle BMAL1 regulates IL-6 and sexual dimorphism of abdominal aortic aneurysm$680,654
R01 · FY2018 · HL
Mineralocorticoid receptor and abdominal aortic aneurysm$519,619
R01 · FY2018 · HL
iPLA2 as a Target in Vascular Inflammation, Neointima Formation, and Restenosis$0
I01 · FY2018 · VA · contact PI
Mineralocorticoid receptor and abdominal aortic aneurysm$519,619
R01 · FY2017 · HL
iPLA2 as a Target in Vascular Inflammation, Neointima Formation, and Restenosis$0
I01 · FY2017 · VA · contact PI
Mineralocorticoid receptor and abdominal aortic aneurysm$519,619
R01 · FY2016 · HL
iPLA2 as a Target in Vascular Inflammation, Neointima Formation, and Restenosis$0
I01 · FY2016 · VA · contact PI
Mineralocorticoid receptor and abdominal aortic aneurysm$531,469
R01 · FY2015 · HL
Regulation of Blood Pressure Circadian Rhythm by Vascular Smooth Muscle BMAL1$468,797
R01 · FY2015 · HL
iPLA2 as a Target in Vascular Inflammation, Neointima Formation, and Restenosis$0
I01 · FY2015 · VA · contact PI
Regulation of Blood Pressure Circadian Rhythm by Vascular Smooth Muscle BMAL1$466,417
R01 · FY2014 · HL
Regulation of Blood Pressure Circadian Rhythm by Vascular Smooth Muscle BMAL1$100,000
R01 · FY2014 · HL
Regulation of Blood Pressure Circadian Rhythm by Vascular Smooth Muscle BMAL1$453,093
R01 · FY2013 · HL
Regulation of Blood Pressure Circadian Rhythm by Vascular Smooth Muscle BMAL1$475,937
R01 · FY2012 · HL
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases$362,588
R01 · FY2012 · HL · contact PI
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases$366,250
R01 · FY2011 · HL · contact PI
ROLE OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2BETA IN HIGH GLUCOSE-INDUCED$8,316
P41 · FY2011 · RR · contact PI
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases$366,250
R01 · FY2010 · HL · contact PI
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases$366,250
R01 · FY2009 · HL · contact PI
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases$258,056
R01 · FY2009 · HL · contact PI
A Novel Mechanism by which iPLA2 Links Diabetes to Cardiovascular Diseases$366,250
R01 · FY2008 · HL · contact PI